3
Orphan Designations
0 approved, 3 designated
0
FDA Approvals
1
Active Trials
200 recruiting
5
Rare Diseases
across 8 areas
0
News (30d)
Quiet
Biostar Pharma, Inc. is a company with 3 orphan drug designations across 5 rare diseases. Active clinical trials in 1 indication. 1 active policy bill affects their portfolio.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| brain neoplasm | - | Des.TrialAppr. |
| breast cancer | utidelone | Des.TrialAppr. |
| familial adenomatous polyposis 1 | utidelone | Des.TrialAppr. |
| gastric cancer | Utidelone | Des.TrialAppr. |
| malignant pancreatic neoplasm | utidelone | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
55
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
1
affecting portfolio
0% of portfolio targets high unmet need diseases
55
overlap in 2+ diseases
0/5
candidate diseases
0
avg importance: 0
1
affecting portfolio